What's in Essentialis, Inc.'s pipeline?

Essentialis, Inc. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Essentialis, Inc.'s portfolio?

Top competitors by shared drug class: Biogen, D'Youville College, National Center for Research Resources (NCRR), Oregon Health and Science University, Orphalan.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/essentialis-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Essentialis, Inc. — Portfolio Competitive Intelligence Brief

Essentialis, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
DCCR	DCCR	phase 3	CDK8 inhibitor	CDK8	Oncology

Therapeutic area mix

Cardiovascular · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Biogen · 1 shared drug class
D'Youville College · 1 shared drug class
National Center for Research Resources (NCRR) · 1 shared drug class
Oregon Health and Science University · 1 shared drug class
Orphalan · 1 shared drug class
Sheba Medical Center · 1 shared drug class
University of Southern Denmark · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Essentialis, Inc.:

Cite this brief

Drug Landscape (2026). Essentialis, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/essentialis-inc. Accessed 2026-05-14.